Premium
Synthesis of tissue inhibitor of metalloproteinase‐1 (TIMP‐1) in human hepatoma cells (HepG2) Up‐regulation by interleukin‐6 and transforming growth factor β1
Author(s) -
Kordula Tomasz,
Güttgemann Ines,
Rose-John Stefan,
Roeb Elke,
Osthues Anja,
Tschesche Harald,
Koj Aleksander,
Heinrich Peter C.,
Graeve Lutz
Publication year - 1992
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/0014-5793(92)81431-k
Subject(s) - tissue inhibitor of metalloproteinase , transforming growth factor , chemistry , metalloproteinase , cancer research , growth factor , microbiology and biotechnology , interleukin , matrix metalloproteinase , medicine , biochemistry , cytokine , biology , receptor
Metalloproteinases and their specific inhibitors, believed to play a role in extracellular matrix metabolism, are regulated by inflammatory cytokines. Here we have addressed the question of whether liver, the major site of Synthesis of plasma proteinase inhibitors, is also capable of synthesizing the tissue inhibitor of metalloproteinase‐1 (TIMP‐1). We show at mRNA and protein levels that TIMP‐1 is expressed in differentiated human hepatoma cells (HepG2) and that its synthesis is up‐regulated by interleukin‐6 (IL‐6), transforming growth factor β1 and phorbol 12‐myristate 13‐acetate. The physiological role of this phenomenon is underlined by the fact that lipopolysaccharide administration into rats in vivo, as well as IL‐6‐stimulation of rat hepatocytes in primary culture, also leads to an increase of TIMP‐1 mRNA in liver cells.